Key result
PPARγ mutations alter receptor dynamics to guide selective modulator design for precision therapy.
Why the study?
Understanding the molecular mechanisms of activating and deactivating PPARγ mutations is needed to guide the design of selective modulators for precision therapy and classify mutations.
Understanding the molecular mechanisms of PPARγ mutations provides insights into metabolic disorders and guides the design of selective modulators for precision therapy.
Mutation effects on PPARγ should not yet alter practice; leaves open validation for selective modulator design.
The nuclear receptor known as peroxisome proliferator-activated receptor gamma (PPARγ) is essential for inflammation, lipid metabolism, glucose homeostasis, and adipogenesis. The function of PPARγ can be significantly impacted by mutations that either activate or deactivate the receptor. Deactivating variants can act as dominant-negative forms that sequester coactivators, impair ligand recognition, destabilize the activation function-2 (AF-2) surface, or favor corepressor binding. They are frequently found in the ligand-binding or DNA-binding domains. Metabolic disorders like severe insulin resistance and familial partial lipodystrophy type 3 are caused by these mutations. Activating mutations provide mechanistic insights into receptor overactivation by stabilizing helix 12 and the AF-2 surface, improving coactivator recruitment, and promoting ligand-independent transcription. These variations change the equilibrium between inactive and active states, modify coactivator binding, and reshape conformational ensembles, as demonstrated by molecular dynamics simulations. The design of selective modulators for precision therapy that target PPARγ is guided by an understanding of these molecular mechanisms, which also help classify mutations as dominant-negative or drug-rescuable.
No takes yet. Share an insight, caveat, or question.
Radwan et al. (2026) conducted a review in PPARγ mutations and associated metabolic disorders. PPARγ activator and deactivator mutations was evaluated. Activating and deactivating mutations in PPARγ alter receptor function and conformational dynamics, providing mechanistic insights for designing selective modulators for precision therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: